Senseonics Holdings Expands with Innovative Diabetes Solutions

An update from Senseonics Holdings ( (SENS) ) is now available.

Senseonics Holdings, Inc. is revolutionizing diabetes management with the Eversense® 365 Continuous Glucose Monitoring (CGM) System, the only fully implantable CGM approved for a year-long duration. Recently cleared by the FDA, the Eversense® 365 addresses key complaints of comfort and accuracy, and targets the underpenetrated $20 billion U.S. CGM market. Partnering with Ascensia Diabetes Care and Mercy Health, Senseonics is poised to expand its market presence, while developing next-gen devices like the self-powering Gemini System and the Freedom System, enhancing user convenience and connectivity.

For a thorough assessment of SENS stock, go to TipRanks’ Stock Analysis page.